Why did HCA raise its 2024 guidance?

HCA raised guidance across revenue, net income, Adjusted EBITDA, and diluted EPS, citing strong patient demand and effective execution of its strategic plan. The filing does not itemize every driver, but the first-half results (6-month net income of $3.052 billion, Adjusted EBITDA of $6.903 billion) and same facility admissions growth of 5.8% underpin the revised outlook.

How much of the EPS growth came from share buybacks versus operating performance?

Both contributed. Diluted share count fell from 278.2 million to 264.1 million, about 5%, which mechanically boosts per-share results. Net income attributable to HCA rose about 22% (from $1.193 billion to $1.461 billion), so operating performance and the lower share count together drove the 29% increase in diluted EPS. Gains on facility sales ($0.03 per share in the quarter) were immaterial to the quarter's result.

Is HCA's debt load a concern?

Total debt of $40.880 billion is substantial, and $4.574 billion of long-term debt is due within one year, up from $2.424 billion at December 31, 2023. Cash of $831 million and $7.137 billion of credit facility availability provide liquidity. The company's refinancing ability is a risk factor the filing explicitly highlights. Investors should weigh this against Adjusted EBITDA of $13.75–$14.25 billion in guidance.

What should investors make of the decline in operating cash flow?

Quarterly operating cash flow fell to $1.971 billion from $2.475 billion year over year, even as earnings rose. The filing does not explain the drop in this release. Working capital changes, including accounts receivable of $10.239 billion (up from $9.958 billion at year-end), and payments on accounts payable likely contributed. Investors should review the 10-Q and earnings call commentary on cash conversion.

What do the volume trends signal for the business?

Admissions and ER visits grew, with same facility ER visits up 5.5% and admissions up 5.8%, showing healthy demand. Outpatient surgeries declined 2.1% while inpatient surgeries rose 2.6%, a mix shift that matters for revenue per case. Growth in revenue per equivalent admission of 4.4% suggests pricing and payer mix are supportive, though the filing lists payer mix and uninsured patient trends as ongoing risks.

HCA 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed July 23, 2024. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported strong second-quarter 2024 results, with revenues of $17.492 billion^a (up from $15.861 billion, roughly 10%), net income attributable to HCA of $1.461 billion, or $5.53 per diluted share (versus $4.29 a year earlier), and Adjusted EBITDA of $3.550 billion, a 20.3% margin versus 19.3% in 2Q 2023.

Volume trends were healthy: same facility admissions rose 5.8%^b, same facility equivalent admissions rose 5.2%, and same facility revenue per equivalent admission increased 4.4%. Emergency room visits grew 5.5%, inpatient surgeries rose 2.6%, and outpatient surgeries declined 2.1%. Management characterized demand as strong and raised its full-year 2024 guidance across all key metrics.

The revised guidance is the central investor takeaway. Revenue guidance moved to $69.75^c–$71.75 billion from $67.75–$70.25 billion, net income attributable to HCA to $5.675–$5.975 billion from $5.200–$5.600 billion, Adjusted EBITDA to $13.75–$14.25 billion from $12.85–$13.55 billion, and diluted EPS to $21.60–$22.80 from $19.70–$21.20. Capital expenditures are expected at $5.1–$5.3 billion.

Share repurchases remain significant: HCA bought back 4.217 million shares for $1.367 billion^d in the quarter and had $4.228 billion left under its authorization. Diluted share count fell to 264.1 million from 278.2 million a year earlier, which amplifies per-share earnings growth. Balance sheet and cash generation warrant monitoring.

Total debt was $40.880 billion at June 30, 2024, against cash of $831 million, and $4.574 billion of long-term debt comes due within one year. Operating cash flow in the quarter fell to $1.971 billion from $2.475 billion a year earlier, a notable decline that the release does not explain in detail. Liquidity was $7.137 billion of credit facility availability.

The Board declared a quarterly dividend of $0.66 per share, payable September 30, 2024 to holders of record on September 16, 2024. Note that the filing's operating cash flow figure for the quarter differs from the six-month figure in the cash flow statement, which is presented separately; investors should rely on the source reconciliation.

02—Key points

Key Highlights

2Q 2024 revenues of $17.492 billion, up roughly 10.3% from $15.861 billion in 2Q 2023
Diluted EPS of $5.53 versus $4.29 in 2Q 2023; Adjusted EBITDA of $3.550 billion with a 20.3% margin (up from 19.3%)
Full-year 2024 guidance raised: Adjusted EBITDA to $13.75–$14.25 billion and diluted EPS to $21.60–$22.80, both above prior ranges
Same facility admissions +5.8% and same facility revenue per equivalent admission +4.4%, indicating both volume and pricing strength
Aggressive share repurchases: 4.217 million shares bought for $1.367 billion in 2Q; diluted share count down about 5% year over year to 264.1 million
Quarterly operating cash flow of $1.971 billion, down from $2.475 billion a year earlier, a point to watch
Quarterly dividend of $0.66 per share declared, payable September 30, 2024

03—Questions

Frequently Asked Questions

Why did HCA raise its 2024 guidance?
HCA raised guidance across revenue, net income, Adjusted EBITDA, and diluted EPS, citing strong patient demand and effective execution of its strategic plan. The filing does not itemize every driver, but the first-half results (6-month net income of $3.052 billion, Adjusted EBITDA of $6.903 billion) and same facility admissions growth of 5.8% underpin the revised outlook.
How much of the EPS growth came from share buybacks versus operating performance?
Both contributed. Diluted share count fell from 278.2 million to 264.1 million, about 5%, which mechanically boosts per-share results. Net income attributable to HCA rose about 22% (from $1.193 billion to $1.461 billion), so operating performance and the lower share count together drove the 29% increase in diluted EPS. Gains on facility sales ($0.03 per share in the quarter) were immaterial to the quarter's result.
Is HCA's debt load a concern?
Total debt of $40.880 billion is substantial, and $4.574 billion of long-term debt is due within one year, up from $2.424 billion at December 31, 2023. Cash of $831 million and $7.137 billion of credit facility availability provide liquidity. The company's refinancing ability is a risk factor the filing explicitly highlights. Investors should weigh this against Adjusted EBITDA of $13.75–$14.25 billion in guidance.
What should investors make of the decline in operating cash flow?
Quarterly operating cash flow fell to $1.971 billion from $2.475 billion year over year, even as earnings rose. The filing does not explain the drop in this release. Working capital changes, including accounts receivable of $10.239 billion (up from $9.958 billion at year-end), and payments on accounts payable likely contributed. Investors should review the 10-Q and earnings call commentary on cash conversion.
What do the volume trends signal for the business?
Admissions and ER visits grew, with same facility ER visits up 5.5% and admissions up 5.8%, showing healthy demand. Outpatient surgeries declined 2.1% while inpatient surgeries rose 2.6%, a mix shift that matters for revenue per case. Growth in revenue per equivalent admission of 4.4% suggests pricing and payer mix are supportive, though the filing lists payer mix and uninsured patient trends as ongoing risks.

04—Continue

← View all 8-K filings